Search results for "MESH: Physician's Practice Patterns"

showing 2 items of 2 documents

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

2011

International audience; Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <6…

MaleParkinson's diseaseEpidemiologyConsensus Development Conferences as TopicParkinson's diseaseMESH: Antiparkinson AgentsDiseaseAntiparkinson AgentsLevodopa0302 clinical medicineMESH: Practice Guidelines as TopicEpidemiology030212 general & internal medicinePractice Patterns Physicians'Initial therapyMESH: Dopamine AgonistsMESH: AgedMESH: Levodopaeducation.field_of_studyMESH: Middle AgedConsensus conferenceParkinson DiseaseMiddle Aged3. Good healthNeurologyDopamine AgonistsPractice Guidelines as TopicMESH: Guideline AdherenceFemaleFranceGuideline Adherencemedicine.drugmedicine.medical_specialtyLevodopaPopulationGuidelines03 medical and health sciencesInternal medicineMedical practicemedicineHumansMESH: Physician's Practice PatternseducationAgedMESH: HumansMESH: Consensus Development Conferences as Topicbusiness.industrymedicine.diseaseMESH: MaleMESH: FrancePopulation based study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and GerontologybusinessMESH: FemaleMESH: Parkinson Disease030217 neurology & neurosurgeryParkinsonism &amp; Related Disorders
researchProduct